LONDON, June 19, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Drug manufacturers in the U.S., as well as globally, have been
facing increasing competition from generic drug makers following
the expiration of patents on several blockbuster drugs. In 2013
alone, patents on drugs with annual sales of nearly $30 billion are set to expire. This will lead to
further generic competition. The "patent cliff" has created
significant challenges for drug manufacturers. The key for drug
companies will be to boost their product pipelines and collaborate
with institutions and biotechnology companies that have developed,
or are developing, potential blockbuster drugs. On Tuesday, June 18, 2013, shares in drug
manufacturers and generic drug companies ended mostly higher,
tracking gains in the broader market. The major movers in the
sector included Dynavax Technologies Corporation (NASDAQ: DVAX),
Warner Chilcott Plc (NASDAQ: WCRX), Avanir Pharmaceuticals Inc.
(NASDAQ: AVNR), and Actavis Inc. (NYSE: ACT). All these companies
are tracked by AAAResearchReports.com. Free technical research on
DVAX, WCRX, AVNR, and ACT can be downloaded upon sign up at
http://www.aaaresearchreports.com/register/
Shares in Dynavax Technologies Corporation tumbled on Tuesday,
extending their losses from previous trading sessions. The
company's shares hit a 52-week low of $0.99 before finishing the day 5.45% lower at
$1.04. A total of 6.57 million shares
were traded, which is well above the daily average volume of 3.30
million. The drug manufacturer's shares have declined by over
13.30% in the last three sessions, and so far this year, the stock
has tumbled over 62.00%. Besides, the company's shares are
currently trading 79.61% below their 52-week high. Sign up today to
read free research report on DVAX at:
http://www.AAAResearchReports.com/DVAX061913.pdf
Warner Chilcott Plc's stock moved 0.33% higher yesterday,
reversing some of its recent losses. The company's shares traded
between $19.64 and $19.88 before
closing the day at $19.75 on a total
of 3.44 million shares traded, which is well below the daily
average volume of 10.64 million. Shares of this drug maker have
dropped by nearly 1.40% in the last three sessions. Since the start
of 2013, the stock has gained over 68.00%, thus outperforming the
S&P 500. The company's shares are currently trading well above
their 50-day and 200-day moving averages. Register to download free
technical analysis on WCRX at:
http://www.AAAResearchReports.com/WCRX061913.pdf
Shares in Avanir Pharmaceuticals Inc. rose sharply on Tuesday,
extending their gains from the previous market
sessions. The company's shares hit an intraday high of $4.62 before ending the day 2.10% higher at
$4.61. It also saw a total of 3.02
million shares traded which is well above the daily average volume
of 2.00 million. Shares of Avanir Pharma have jumped by over 8.20%
in the last three sessions. So far this year, the stock has gained
over 79.00%, hence outperforming the S&P 500. Moreover, the
company's shares are currently trading 3.56% below their 52-week
high. A free report on AVNR can be accessed by registering at:
http://www.AAAResearchReports.com/AVNR061913.pdf
Actavis Inc.'s stock saw a surge on Tuesday, closing at
$125.67, up 0.58% from its previous
closing price. The company's shares traded between $124.44 and $126.27 on total of 621,683 shares
traded which is well below the daily average volume of 2.06
million. Actavis' shares are now down by over 0.60% in the last
three trading sessions. Furthermore, the stock is currently trading
above its 50-day and 200-day moving averages. Register with AAA
Research Reports and download the research on ACT for free at:
http://www.AAAResearchReports.com/ACT061913.pdf
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
SOURCE AAA Research Reports
